Financial Snapshot

Revenue
$109.9K
TTM
Gross Margin
74.36%
TTM
Net Earnings
-$753.2K
TTM
Current Assets
$242.6K
Q3 2021
Current Liabilities
$8.579M
Q3 2021
Current Ratio
2.83%
Q3 2021
Total Assets
$396.5K
Q3 2021
Total Liabilities
$8.579M
Q3 2021
Book Value
-$8.182M
Q3 2021
Cash
$6.980K
Q3 2021
P/E
-0.05311
May 15, 2024 EST
Free Cash Flow
$61.60K
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

No data

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

No data

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

No data

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

No data

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

No data

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

No data

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $40 Thousand

About Advanced Biomedical Technologies Inc.

Advanced BioMedical Technologies, Inc. engages in the business of designing, developing, manufacturing, and marketing biomaterial internal fixation devices. The company is headquartered in New York City, New York. The company went IPO on 2007-09-10. The Company’s primary products include Polymer Osteosynthesis Devices made of a proprietary material compositing of polyamide 6 (PA6), hydroxyapatite (HA) and poly (methyl methacrylate-co-N-vinylpyrrolidone) (P(MMA-co-NVP)). These advanced materials are used in surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, and reconstructive dental procedures. Its PA Binding Wires are under clinical trials and its PA Mini-Screws are under animal test.

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies Peers: ABBOTT LABORATORIES Bionik Laboratories Corp. ThermoGenesis Holdings, Inc. CYduct Diagnostics, Inc. INVIVO THERAPEUTICS HOLDINGS CORP. ECGI Holdings, Inc. ENCISION INC Wellness Center USA, Inc.